The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility.
B
B
Jahrsdorfer
S
S
Blackwell
G
G
Weiner
D017209:Apoptosis; D049109:Cell Proliferation; D018899:CpG Islands; D003582:Cytogenetics; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000628:therapy; D008954:Models, Biological; D008957:Models, Genetic; D009838:Oligodeoxyribonucleotides / Q000235:genetics*; D010641:Phenotype; D011379:Prognosis; D013601:T-Lymphocytes / Q000378:metabolism; D016896:Treatment Outcome
C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides